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combined biomarker consisting of high numbers of CD14 ++ CD16 + cells together with high expression of angiotensin-converting enzyme (ACE) on these cells for mortality in CKD Stage V D (dialysis) patients. Methods. In a prospective observational study, monocyte subpopulations were enumerated and ACE expression was quantified in 74 CKD patients by flow cytometry. Patients were assigned to one of four groups according to monocyte population numbers and ACE expression below and above the respective medians and observed for mortality and cardiovascular events for 46 months. Results. Patients stratified to the 'high CD14 ++ CD16 + , high ACE' group (n = 22) had a dramatically enhanced mortality of 70% at 2 years compared to all other patient groups (mortality 14.8%, HR 4.86 [95% CI 2.17-10.86,
Introduction
The burden of cardiovascular disease in patients with chronic renal failure remains insufficiently understood. In chronic kidney disease (CKD) Stage V D patients, atherosclerosis cannot be fully explained by traditional cardiovascular risk factors such as hypertension, smoking or dyslipidaemia [1] and the additional role of inflammation is now widely accepted. High levels of C-reactive protein (CRP) [2, 3] or plasma interleukin-6 [4] as markers of systemic inflammation are associated with cardiovascular mortality.
Inflammation is not only a phenomenon of plasma acute-phase proteins but also of alterations in circulating pools of blood immune cells. We [5] and others [6] described high cell counts of certain monocyte populations that are characterized by the simultaneous expression of the lipopolysaccharide (LPS) receptor CD14 and the immunoglobulin Fcγ receptor CD16 in CKD patients.
Based on the expression pattern of these two markers, at least three distinct populations can be reliably distinguished by flow cytometry [7] . A subpopulation expressing solely CD14 (CD14 ++ CD16 − , here termed 'Mo1') can be separated from a population with high-level expression of both antigens (CD14 ++ CD16 + , 'Mo2') and a third population with low expression of CD14 together with high expression of CD16 (CD14 + CD16 + , 'Mo3') (see further explanation in [8] ). The individual size of the rather small Mo2 cell population proved to be highly predictive for cardiovascular events in CKD Stage V D patients [9] . This predictive value was independent from and additive to that of plasma CRP.
Monocytes are directly involved in the pathogenesis of atherosclerosis. They are found within the atherosclerotic plaques where their presence is associated with plaque instability [10] . Several studies noted that monocytes or macrophages within atherosclerotic plaques express the angiotensin-converting enzyme (ACE, CD143) on their surface [11, 12] . The presence of this enzyme within the vessel wall lesion may be relevant for the progression of atherosclerosis. Local angiotensin activation by ACE may induce local oxidative stress and further endothelial damage [13] . Our group found that the expression of ACE on circulating monocytes, while being upregulated in end-stage renal disease (ESRD), is a marker for the presence of cardiovascular disease in these patients in a cross-sectional study [8] .
Based on our earlier findings, this prospective observational pilot study was set up to determine the prognostic relevance of a combined biomarker including the frequency of Mo2 cells together with the individual expression density of ACE for cardiovascular events and mortality in patients on regular dialysis treatment.
Materials and methods

Patients
We recruited 74 patients with CKD Stage V (64 on haemodialysis and 10 on peritoneal dialysis) from the outpatient dialysis facility of the University Hospital of the Saarland at Homburg/Saar, Germany. All patients of this centre who were on dialysis treatment with the same modality for at least 2 months and agreed with participation were considered. Exclusion criteria were immunosuppressive medication for a renal transplant or other causes and acute illnesses requiring hospitalization. Patients had blood samples drawn in November 2003 and were followed up prospectively until August 2008. The causes of renal disease were: diabetic nephropathy (24 patients), glomerulonephritis (17) , polycystic kidney disease (six), interstitial disease (nine), nephrosclerosis (five), unknown (13) . Cross-sectional data on these patients have been recently reported [8] . The study was conducted in adherence to the Declaration of Helsinki, all patients gave informed consent and the study was approved by the local ethics committee.
Clinical procedures
Haemodialysis was performed using bicarbonate dialysate and polyamide (n = 18; Gambro Hospal, Gröbenzell, Germany) or polysulphone (n = 17; Fresenius Medical Care, Bad Homburg, Germany) high-flux or haemophane (n = 29; Gambro Hospal) low-flux dialysers. Peritoneal dialysis was performed using standard peritoneal dialysis solutions (Physioneal/ Dianeal, Baxter, Unterschleißheim, Germany or Stay Safe/Balance, Fresenius Medical Care, Bad Homburg, Germany).
Patients with self-reported diabetes mellitus, with a spontaneous plasma glucose level of >200 mg/dl and/or with hypoglycaemic treatment were categorized as diabetic. Body mass index (BMI) was calculated as weight (in kilogrammes)/height (in metres) 2 . Comorbidity was assessed by chart review and by standardised interviews. Pre-existing cardiovascular disease was diagnosed in patients with a history of myocardial infarction, coronary artery angioplasty/stenting/ bypass surgery, major stroke, carotid endarterectomy/stenting, non-traumatic lower extremity amputation above the ankle or lower limb artery bypass surgery/angioplasty/stenting.
The causes of death were taken from the official death certificate whenever possible. Autopsies for the ascertainment of the death cause were not done. Only deaths from documented myocardial infarction, ischaemia cerebral events or mesenteric ischaemia were counted as 'atherosclerosis-associated deaths'. The pre-specified clinical end points were death and cardiovascular events, defined as myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, major stroke, carotid endarterectomy/stenting, non-traumatic lower extremity amputation or lower limb artery bypass surgery/angioplasty/stenting.
Laboratory methods
Blood was drawn before the start of the mid-week haemodialysis session in haemodialysis patients and during an outpatient clinic appointment in peritoneal dialysis patients and all samples were analysed immediately within 4 h. All measurements were taken once at study entry. Only for a restricted number of patients (n = 27), monocyte measurements were repeated after 22 months to confirm reproducibility of the results. Plasma glucose, total cholesterol, urea, calcium, phosphorus, albumin, haemoglobin and CRP were obtained using standard clinical chemistry techniques. Leucocyte and monocyte counts were measured with automated cell counters by standard techniques.
Monocyte subpopulations were flow cytometrically analysed in a whole blood assay using 100 μl of heparin anti-coagulated blood, as described before [8] . In brief, cells were stained by monoclonal antibodies (as listed below) and analysed by flow cytometry (FACSCalibur, BD Biosciences, Heidelberg, Germany) using the Cell Quest software. Monocytes were gated in a SSC/CD86 + dot plot, identifying monocytes as CD86
+ cells with monocyte scatter properties. Subsets of CD14 ++ CD16 − , CD14 ++ CD16 + and CD14 + CD16 + monocytes were defined as reported before [8] . Absolute numbers of monocyte subpopulations were calculated from the relative frequency among the monocytes as measured into the SSC/CD86 gate multiplied by the monocyte number determined by a differential cell count. The following antibodies were used: CD86 (HA5.2B7, Beckman-Coulter, Krefeld, Germany), CD16 (3G8, Invitrogen, Karlsruhe, Germany), CD14 (Mϕ9, BD Biosciences), CD143 (9B9, Serotec, Düsseldorf, Germany).
Serum ACE activity was measured by a spectrophotometric (UV kinetic) method utilizing hydrolysis of the synthetic substrate N-FAPGG (normal range, 8-52 U/L) [14] .
Statistical analysis
Categorical variables are presented as percentage of patients. Continuous data are expressed as means ± standard deviation and compared by ANOVA. Regression coefficients were calculated by linear regression analysis. For grouping of patients according to monocyte numbers and ACE expression density, groups were formed from those greater than or equal to and less than the respective median of all patients. Kaplan-Meier survival curves were used to compare survival (or event-free survival, respectively) by patient group. The Mantel-Cox log rank test was used to test the hypothesis that at least one of the survival curves differs from the others.
Cox proportional hazards models were calculated to study the relationships of monocyte subpopulation numbers and ACE expression density with survival, adjusting for age, dialysis vintage, CRP and the use of angiotensin-blocking medication.
Data management and statistical analysis were performed with the SPSS 17.0 statistical software (SPSS, München, Germany) and the Prism 5.02 software (GraphPad, San Diego, USA). The level of significance was predefined at P < 0.05.
Results
Participants and detection of monocyte subpopulations
The study included 74 patients with CKD Stage V D on renal replacement therapy. The demographic and clinical parameters are described in Table 1 .
The patients were prospectively characterized by the quantification of monocyte subpopulations in the circulation before the mid-week dialysis session. Monocytes were separated into three different groups according to the expression of the LPS receptor CD14 and the Fcγ receptor CD16. As described earlier, a subpopulation expressing solely CD14 (CD14 ++ CD16 − , Mo1) can clearly be separated from a population with high-level expression of both antigens (CD14 ++ CD16 + , Mo2) and a further population with low expression of CD14 together with high expression of CD16 (CD14 + CD16 + , Mo3). The Mo1 population is by far the largest circulating subpopulation (Table 2) . Nearly two-thirds of the cells show the Mo1 characteristics.
Monocytes express the ACE (CD143) on their surface. This expression is nearly twice as high in the Mo2 population compared to Mo1 and Mo3 ( Figure 1A ). The interindividual distribution of expression levels of ACE on the Mo1 and Mo2 monocytes was rather broad over the patient population ( Figure 1B ). ACE expression on the three monocyte populations correlated closely (r = 0.94, P < 0.0001; Mo1 vs Mo2); however, the expression was highest on Mo2 in all individuals (data not shown).
Prospective follow-up
All patients were included in the study in November 2003 and were followed up until censoring, death or 31 August 2008. During this time, all cardiovascular events were registered. No patient was lost to follow-up, 17 patients received a renal transplant and were censored. The average follow-up time was 31.3 ± 20.8 months. During the observation period, 38 patients died; among them, seven were clearly consecutive to a cardiovascular event. There may have been more cases of cardiovascular death among those who died; however, several patients died outside the hospital and their causes of death remained uncertain. The annual mortality was 18.6% during the first year and 18.0% during the second year of follow-up.
Predictive value of monocyte populations and ACE expression
The absolute numbers of Mo2 monocytes in the circulation at study entry were predictive for mortality. This could also be confirmed for Mo1 cells, while Mo3 numbers did not predict mortality (Figure 2 ). In addition, the expression levels of ACE on Mo1 and Mo2 monocyte subpopulations were predictive for mortality, while this was not the case for ACE expression density on Mo3 cells (Figure 2 ). The absolute numbers of the Mo2 subtype and the expression density of ACE on this cell type as a combined biomarker proved to be a surprisingly precise predictor of mortality (Figure 3 ). Dividing both parameters by the median, 22 patients had low numbers of Mo2 cells and a low expression density of ACE on this cell type. Fifteen patients each had high Mo2 numbers together with low ACE density or vice versa. A further 22 patients showed high Mo2 numbers together with high expression density for ACE. The latter group had a dramatically lower survival compared to all other individuals (Figure 3) . Therefore, the marker combination high Mo2 number and high expression level of ACE on this cell population was strongly predictive for mortality (HR 4.86 [95% CI 2.17-10.86, P < 0.0001], Mo2 and ACE high vs all other patients). A similar prediction could be found using the combined biomarker of Mo1 cell number and ACE expression on Mo1 cells. However, due to the higher expression density of ACE on Mo2, all further analysis relates solely to that cell type.
The predictive value could be confirmed after excluding the 10 peritoneal dialysis patients from the analysis (see the supplementary material). Furthermore, it remained significant in a multivariate analysis of the whole study group after including age, dialysis vintage and CRP into the Cox model. Twenty patients received angiotensin-blocking medication (six ACE inhibitors, 11 angiotensin receptor blockers, three both). Angiotensin blockers were used in 11 out of 37 patients (30%) of the groups expressing low levels of surface ACE and in nine out of 37 patients (24%) of those with high membrane ACE. Including the use of either ACE inhibitors or angiotensin receptor blockers into the multivariate model did not alter the results. In addition, we found no hint that patients with diabetes mellitus differed from non-diabetics with regard to the monocyte/ACE biomarker.
The causes of death in relation to the Mo2 numbers and ACE expression are listed in Table 3 . These data, however, have to be interpreted with caution. Those listed as cardiovascular deaths were patients who died from either acute myocardial infarction, ischaemic cerebral insult or mesenteric ischaemia. There are several patients in whom cardiovascular death may be suspected; however, this remains unproven as they either died outside the hospital or death was most likely due to arrhythmia. The data might suggest a higher prevalence of atherosclerosis-associated causes of death in the patient group with high Mo2 numbers and high ACE expression. The rate of clearly atherosclerosisassociated events among the deaths was 35% in the Mo2-high, ACE-high group compared to 5% in all other patients.
The study also recorded cardiovascular events throughout the follow-up. The combined biomarker high Mo2 number and high expression of ACE predicted the composed end point of cardiovascular events and death (HR 3.48 [95% CI 1.66-7.27, P < 0.001], Mo2 and ACE high vs all other patients, univariate analysis).
Stability of the ACE expression measurements
The level of ACE expression on monocytes was rather stable over time. Measurements were repeated after 22 months in 27 patients ( Figure 4) . The results between both measurements correlated closely (r = 0.70). As could be expected for measurements of mean fluorescence intensity, the absolute values differed to a certain extent (lower in the second round); however, the relation of expression densities within the patient group remained the same. The same was true for circulating Mo2 numbers, however, with some more variability (correlation coefficient between first and second measurement, r = 0.51). Nevertheless, the study was not designed to gain follow-up expression data per protocol. Thus, there is no information on the development of ACE expression levels in those individuals who died or suffered from events during the study period.
Relation to age and dialysis vintage
A potential interpretation for the extremely high mortality in patients with high numbers of Mo2 and high ACE expression might be that these cellular characteristics are some kind of a priori markers for short dialysis survival. As an alternative explanation, the combination of cellular biomarkers might develop during end-stage renal failure just a few months before death (2-year mortality in the Mo2/ACE-high group, 70%). Until prospective repeat measurements by protocol are available, only indirect evidence suggests that the latter interpretation might be correct. If the marker combination had been present in the patient from the beginning of kidney disease, the dialysis vintage at study entry should be clearly lower in the Mo2/ ACE-high group. This could not be confirmed in our patient group (Table 4) . The time the patients had been on dialysis was rather high in the Mo2/ACE-high group.
Relation to soluble markers of inflammation
As has been shown before, the predictive value of monocyte cell counts was independent from soluble inflammatory markers. This holds true also for the combined marker of Mo2 cell number and ACE expression (Table 5 ). In addition, the patients with higher expression of ACE on monocytes did not have higher ACE plasma activity, indicating that monocyte ACE is not the major source of circulating ACE but a component of a local angiotensin system, e.g. at sites that may be infiltrated by the monocyte/macrophage.
Discussion
The detection of high numbers of monocyte subpopulation Mo2 (expressing CD14 ++ CD16 + ) in the circulation together (1) Uncertain (6) a Cases that were counted as atherosclerosis-associated. Fig. 3 . Kaplan-Meier survival curves of patients with low or high percentage of circulating Mo2 cells combined with low or high expression of ACE on this cell type; the group with high Mo2 numbers together with high ACE expression had a significantly lower survival compared to all other groups (P < 0.0001 by log rank test). Fig. 4 . Reproducibility of the ACE expression density measurement on Mo2: in 27 patients, the initial measurements of ACE expression on Mo2 cells were repeated 22 months after the start of the study (r = 0.70, P < 0.0001).
with high expression of ACE on this cell type is a sign of worse prognosis in patients with CKD Stage V D . Within 1 year after the detection of this marker combination, 50% of the patients died. Another 12 months later, <1 in three patients was still alive. In contrast, mortality in patients of similar age and comorbidity was 6% after 1 year and 15% at 2 years if they did not have high Mo2 levels with high ACE expression at study entry.
Our group previously established that high circulating numbers of Mo2 monocytes predict cardiovascular events in CKD patients [9] . In that study, a tendency toward the same predictive effect was found for Mo1 cells; however, this was not statistically significant (P = 0.061). This formal discrepancy to our present data most likely results from different statistical techniques: the previous study analysed quartiles of the monocyte numbers; here, we divided our study group along the median in order to allow combined analysis with ACE expression later on. The interpretation of the data should acknowledge that we cannot prove a difference between Mo1 and Mo2 in their predictive value for mortality in ESRD patients.
Monocytes express ACE on their surface. This expression is stronger on Mo2 monocytes than on any other monocyte subpopulation. This is why we concentrated on the evaluation of Mo2 cells in the survival analysis. High expression of ACE on Mo2 cells was associated with the presence of cardiovascular disease in end-stage renal failure in the cross-sectional observation of our patient group [8] . The present study confirms the role of Mo2 ACE expression in a prospective observational design. However, due to the difficulties of studying monocyte populations in patients (need for fresh blood samples, technical limitations to shipment of samples), the sample size of this study is small and we regard it as a pilot study rather than final proof.
It is not yet clear why the marker combination has this astonishingly strong predictive value. Indirect evidence suggests that the high number of strongly ACE-expressing monocytes develops during the course of long-term dialysis treatment a few months before the patient dies. The dialysis vintage at study entry was not shorter for the patients when compared to those without the sinister marker combination. If it were shorter, these patients might have had a higher a priori risk to die, which does not seem to be the case. Unfortunately, our study did not include serial detections of the respective markers which could have proven the de novo occurrence in patients. It is of particular interest that there was no clear association between Mo2 numbers, ACE expression and the combined biomarker and age of the patient. Only those patients with low Mo2 numbers and low ACE expression tended to be younger. Most likely, the potential confounding effect of age was minimized in our study due to the fact that we studied a rather homogenously old group of patients (65.3 ± 14.6 years, median 68.4 years).
Although our study is underpowered to prove this, the data suggest that there were more deaths related to atherosclerosis in those patients with high Mo2 numbers and high ACE expression than in the other patient groups. Infections and cardiovascular disease are the main causes of death in CKD Stage V D patients [15] . However, as in most studies in these patients, it is difficult to separate atherosclerosis-related events from other cardiac events. In addition, many dialysis patients die at home, not at the dialysis facility. We classified the causes of death in a very conservative way. Only clearly atherosclerosis-associated events such as acute myocardial infarction, ischaemic cerebral events or abdominal ischaemia were counted. The rate of atherosclerosis-associated events among the deaths was 35% in the Mo2-high, ACE-high group compared to 5% in all other patients.
Monocytes of the Mo1 and Mo2 types with high levels of ACE might be more aggressive cells to the vascular endothelium compared to Mo3 populations. In the past, CD16 + monocytes were thought to be 'pro-inflammatory' monocytes [16] , although this concept is still debated.
More recent findings suggest a broader picture of differential tasks for monocyte subpopulations [7, 17, 18] . Several differences between the monocyte fractions were detected by Affymetrix RNA gene expression profiling, leading to the impression that CD14 ++ CD16
− (Mo1) cells have mostly regulatory functions in close association with neutrophils, while the CD14 ++ CD16 + (Mo2) cells express numerous genes relevant to antibacterial activity [17] . This concept is in line with findings in the murine model. Mouse monocytes do not express CD14 and CD16; however, functionally similar cell populations can be identif ied by the expression of CD62L, which is shared between mouse and man. In humans, Mo1 cells express CD62L at a high level, while Mo2 have been described as CD62L-negative [7] . According to our observations, human Mo2 seem to be CD62L low (unpublished No significant differences could be detected between the four groups by ANOVA.
In a very elegant murine model using confocal intravital microscopy, Auffray and co-workers visualized that monocytes use to crawl along the endothelium of arteries and veins independent from the blood stream [19] . The authors describe this behaviour as 'patrolling the endothelium'. These cells stay within the blood vessel unless tissue damage leads to rapid local extravasation. Most interestingly with regard to our present study is the finding that the patrolling monocytes in mice are predominantly Ly6C-negative. Human Mo2 cells possibly correspond to a part of the Ly6C low negative population and may, therefore, have similar functions. Further research will have to show if the role of Mo1 and Mo2 cells in atherosclerosis can be clearly distinguished.
In the animal model of atherosclerosis of apoE −/− mice, the invasion of monocytes into atherosclerotic plaques within the vessel walls could be directly demonstrated [20] . Both, Ly6C
+ and Ly6C − monocytes were able to transmigrate into the atherosclerotic plaque. The molecular mechanisms leading to endothelial adhesion and transmigration differ between Ly6C + and Ly6C − cells in mice [20] . Both cell types express different patterns of chemokine receptors and have different signalling requirements for transendothelial migration; however, both seem to be relevant for the composition of atherosclerotic plaques. This fits with our observation that there was no difference in prediction for atherosclerosis between Mo1 and Mo2 cells.
The presence of monocytes and monocyte-derived macrophages as constituents of the human atherosclerotic plaque has long been known [21] . Earlier studies also showed that ACE is expressed within the atherosclerotic plaques. It co-localizes with infiltrating monocytes [12] , supporting the concept that monocytes significantly contribute to the introduction of this enzyme into the vessel wall lesion [11] . High expression of ACE in macrophages was found post-mortem in ruptured coronary plaques, while stable plaques lacked this predominant monocytic ACE [22] .
Locally acting ACE within the vessel wall may be an important contribution to progressive atherosclerosis. The enzyme produces angiotensin II from its precursor, a hormone with pro-inflammatory and pro-oxidative activity which contributes to impaired endothelial function [13, 23] . Inhibition of ACE reduces the size of vascular plaques in ApoE −/− atherosclerotic mice [24] , while angiotensin II infusions induce plaque growth and macrophage accumulation in the vascular wall [25] .
In conclusion, our finding of a surprisingly strong predictive value of a combined biomarker consisting of the number of circulating CD14 ++ CD16 + monocytes together with a high level of expression of ACE on these cells for mortality of patients with ESRD points toward a causal role of this cell type for atherosclerosis. Therefore, further research into the conditions leading to the development of high numbers of these cells with high ACE expression is justified.
